You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Article metrics

Article menu

Download PDFPDF

Research Article
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 2019110
Jan 2020330
Feb 202015153
Mar 202012122
Apr 2020121216
May 202017175
Jun 2020993
Jul 202018180
Aug 2020887
Sep 202035356
Oct 202016160
Nov 202015153
Dec 2020994
Jan 202115155
Feb 202111116
Mar 2021440
Apr 2021993
May 2021661
Jun 202119192
Jul 202111113
Aug 2021881
Sep 202118186
Oct 202110101
Nov 202112122
Dec 202124246
Jan 202217181
Feb 202222228
Mar 202221226
Apr 202221246
May 202232320
Jun 202226282
Jul 202223241
Aug 2022263410
Sep 202223259
Oct 202223255
Nov 2022222413
Dec 202222232
Jan 202318181
Feb 202339390
Mar 2023232413
Apr 2023131412
May 2023773
Jun 2023993
Jul 202322227
Aug 202311111
Sep 202315151
Oct 202312122
Nov 202354541
Dec 20231601607
Jan 202435363
Feb 202426276
Mar 2024212114
Total10601087222